<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04394091</url>
  </required_header>
  <id_info>
    <org_study_id>ultrasensitive PET/CT in NPC</org_study_id>
    <nct_id>NCT04394091</nct_id>
  </id_info>
  <brief_title>Post-treatment Ultrasensitive Positron Emission Tomography in Nasopharyngeal Carcinoma Patients</brief_title>
  <official_title>Post-treatment Ultrasensitive Positron Emission Tomography in Nasopharyngeal Carcinoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      NPC Patients receiving IMRT treatment will receive a dedicated FDG PET/CT and
      high-sensitivity PET/CT protocol simultaneously in the follow-up of Locally Advanced
      Nasopharyngeal Carcinoma. Hence we establish this prospective cohort study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Newly-diagnosed patients with stage III or IV non-metastatic Nasopharyngeal Carcinoma (AJCC
      8th) will be recruited. All subjects receiving chemoradiotherapy will undergo a baseline
      integrated [18F]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography/computed
      tomography (PET/CT) scan or traditional follow-up examination before the start of
      chemoradiotherapy.

      NPC Patients receiving IMRT treatment will receive a dedicated FDG PET/CT and
      high-sensitivity PET/CT protocol simultaneously 12 weeks after the end of chemoradiotherapy
      (primary endpoint).

      The results of FDG PET/CT and high-sensitivity PET/CT analyzed and compared.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 20, 2020</start_date>
  <completion_date type="Anticipated">December 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>results of ultrasensitive and normal PET CT</measure>
    <time_frame>6 months</time_frame>
    <description>The results of the two tests were compared to verify the specificity and sensitivity of ultrasensitive PET CT in post treatment NPC</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>PET CT and ultrasensitive PET CT</arm_group_label>
    <description>Patients receiving chemoradiotherapy will receive a dedicated FDG PET/CT and ultrasensitive PET CT protocol 12 weeks after the end of IMRT .</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ultrasensitive PET CT</intervention_name>
    <description>A 194-cm-long total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER), has been constructed to offer a transformative platform for human radiotracer imaging in clinical research and healthcare. Its total-body coverage and exceptional sensitivity provide opportunities for innovative studies of physiology, biochemistry, and pharmacology.</description>
    <arm_group_label>PET CT and ultrasensitive PET CT</arm_group_label>
    <other_name>PET CT</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        NPC patients after induction chemotherapy and concurrent chemoradiotherapy or concurrent
        chemoradiotherapy alone
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be informed of the investigational nature of this study and given
             written informed consent.

          -  Aged between 18-70, male/female.

          -  Staged III or IV (AJCC 8th) NPC patients with histologically confirmed
             non-keratinizing nasopharyngeal carcinoma (including differentiated type and
             undifferentiated type, WHO II and III).

          -  Received induction chemotherapy and/or concurrent chemoradiotherapy. ECOG scale 0-1.

          -  Fertile women should practice contraception during the study period.

          -  HGB ≥90g/L ,WBC ≥4*109/L , PLT ≥100*109/L,

          -  With normal liver function test (ALT and AST ≤2.5*ULN, TBil ≤2.0*ULN)

          -  With normal renal function test (serum creatinine ≤1.5*ULN)

        Exclusion Criteria:

          -  Women in pregnancy or lactation

          -  Prior malignancy except adequately treated basal cell, squamous cell skin cancer, or
             cervical cancer in situ.

          -  Any severe intercurrent disease, which may bring unacceptable risk or affect the
             compliance of the trial, for example, unstable cardiac disease requiring treatment,
             renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose
             &gt;1.5×ULN), and emotional disturbance.

          -  Already involved in other clinical trial.

          -  Mental disorder, civil disability, limited capacity for civil conduct.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haiqiang Mai, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haiqiang Mai, Dr</last_name>
    <phone>86-20-8734-3643</phone>
    <email>maihq@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Zhang X, Cherry SR, Xie Z, Shi H, Badawi RD, Qi J. Subsecond total-body imaging using ultrasensitive positron emission tomography. Proc Natl Acad Sci U S A. 2020 Feb 4;117(5):2265-2267. doi: 10.1073/pnas.1917379117. Epub 2020 Jan 21.</citation>
    <PMID>31964808</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang X, Xie Z, Berg E, Judenhofer MS, Liu W, Xu T, Ding Y, Lv Y, Dong Y, Deng Z, Tang S, Shi H, Hu P, Chen S, Bao J, Li H, Zhou J, Wang G, Cherry SR, Badawi RD, Qi J. Total-Body Dynamic Reconstruction and Parametric Imaging on the uEXPLORER. J Nucl Med. 2020 Feb;61(2):285-291. doi: 10.2967/jnumed.119.230565. Epub 2019 Jul 13.</citation>
    <PMID>31302637</PMID>
  </results_reference>
  <results_reference>
    <citation>Lv Y, Lv X, Liu W, Judenhofer MS, Zwingenberger A, Wisner E, Berg E, McKenney S, Leung E, Spencer BA, Cherry SR, Badawi RD. Mini EXPLORER II: a prototype high-sensitivity PET/CT scanner for companion animal whole body and human brain scanning. Phys Med Biol. 2019 Mar 21;64(7):075004. doi: 10.1088/1361-6560/aafc6c.</citation>
    <PMID>30620929</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 12, 2020</study_first_submitted>
  <study_first_submitted_qc>May 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Hai-Qiang Mai,MD,PhD</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <keyword>high-sensitivity PET CT</keyword>
  <keyword>PET CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

